Trastuzumab Emtansine for Residual Invasive Human Epidermal Growth Receptor-2-Positive Breast Cancer

Joydeep Ghosh; Atul Batra; Amol Patel; Prashant Mehta

doi:10.4103/ijmpo.ijmpo_255_19

Indian Journal of Medical and Paediatric Oncology, Table of Contents

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(05): 652-653
DOI: 10.4103/ijmpo.ijmpo_255_19

Editorial Commentary

Trastuzumab Emtansine for Residual Invasive Human Epidermal Growth Receptor-2-Positive Breast Cancer

Joydeep Ghosh

Department of Medical Oncology, Tata Medical Centre, Kolkata, West Bengal, India

,

Atul Batra

Department of Medical Oncology, AIIMS, New Delhi, India

,

Amol Patel

Malignant Diseases Treatment Centre, Army Hospital Research and Referral, New Delhi, India

,

Prashant Mehta

Department of Medical Oncology/Hematology/BMT, Asian Institute of Medical Sciences, Faridabad, Haryana, India

› Author Affiliations

Abstract

Full Text

References

References
1 Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I. et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 2017; 376: 2147-59
2 von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M. et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 2019; 380: 617-28
3 von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G. et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 2017; 377: 122-31
4 Mavroudis D, Saloustros E, Malamos N, Kakolyris S, Boukovinas I, Papakotoulas P. et al. Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: A multicenter randomized study by the Hellenic Oncology Research Group (HORG). Ann Oncol 2015; 26: 1333-40
5 Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T. et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): A randomised phase 3 trial. Lancet Oncol 2013; 14: 741-8
6 Romond EH, Jeong JH, Rastogi P, Swain SM, Geyer Jr. CE, Ewer MS. et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012; 30: 3792-9
7 NALA Trial-The ASCO Post. https://www.ascopost.com/issues/july-10-2019/nala-trial/. Available from: [Last accessed on 2019 Oct 08]
8 Fabi A, Alesini D, Valle E, Moscetti L, Caputo R, Caruso M. et al. T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer. Breast 2018; 41: 137-43
9 Bartsch R, Berghoff AS, Vogl U, Rudas M, Bergen E, Dubsky P. et al. Activity of T-DM1 in Her2-positive breast cancer brain metastases. Clin Exp Metastasis 2015; 32: 729-37